IP Verse

Method And Compositions For Cellular Immunotherapy - EP2884999

The patent EP2884999 was granted to Fred Hutchinson Cancer Center on Oct 8, 2025. The application was originally filed on Aug 20, 2013 under application number EP13753495A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2884999

FRED HUTCHINSON CANCER CENTER
Application Number
EP13753495A
Filing Date
Aug 20, 2013
Status
Patent Maintained As Amended
Sep 5, 2025
Grant Date
Oct 8, 2025
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

KONIG SZYNKA TILMANN VON RENESSEApr 9, 2021KLUNKERADMISSIBLE
KONIG SZYNKA TILMANN VON RENESSEApr 9, 2021KONIG SZYNKA TILMANN VON RENESSE PATENTANWALTE PARTNERSCHAFT MBB DUSSELDORFADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO1991US08442-
DESCRIPTIONWO1994US05601-
DESCRIPTIONUS6040177
INTERNATIONAL-SEARCH-REPORTWO02077029
INTERNATIONAL-SEARCH-REPORTWO2012129514
OPPOSITIONWO2011056894
OPPOSITIONWO2014031687

Non-Patent Literature (NPL) Citations (65) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ALTSCHUL ET AL., METHODS IN ENZYMOLOGY, (1996), vol. 266, pages 460 - 480-
DESCRIPTION- CHO, NATURE, (2003), vol. 421, page 756-
DESCRIPTION- FITZER-ATTAS CJ ET AL., "Hamessing Syk family tyrosine kinases as signaling domains for chimeric single chain of the variablc domain rcccptors: optimal design for T ccll activation", J IMMUNOL., (19980429), vol. 160, no. 1, pages 145 - 54-
DESCRIPTION- HUDECEK M ET AL., BLOOD, (20100813), vol. 116, no. 22, pages 4532 - 41-
DESCRIPTION- LUPTON S. D. ET AL., MOL. AND CELL BIOL., (1991), vol. 11, page 6-
DESCRIPTION- RIDDELL ET AL., HUMAN GENE THERAPY, (1992), vol. 3, pages 319 - 338-
DESCRIPTION- RIDDELL SR; GREENBERG PD, "The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells", J IMMUNOL METHODS, (19900417), vol. 128, no. 2, doi:doi:10.1016/0022-1759(90)90210-M, pages 189 - 201, XP025462287
INTERNATIONAL-SEARCH-REPORT- PHILIPP KOEHLER ET AL, "Engineered T Cells for the Adoptive Therapy of B-Cell Chronic Lymphocytic Leukaemia", ADVANCES IN HEMATOLOGY, (20120101), vol. 180, no. 9, doi:10.1073/pnas.0710198105, ISSN 1687-9104, pages 6365 - 13, XP055094721 [X] 1-25 * page 2 - page 3 * * page 8 - page 9; table 1 * [Y] 26-35
INTERNATIONAL-SEARCH-REPORT- TILL BRIAN G ET AL, "Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells", BLOOD, (200809), vol. 112, no. 6, ISSN 0006-4971, pages 2261 - 2271, XP002718371 [X] 1-25 * page 2263; figure 2 * [Y] 26-35
INTERNATIONAL-SEARCH-REPORT- M. HUDECEK ET AL, "The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor", BLOOD, (20101125), vol. 116, no. 22, doi:10.1182/blood-2010-05-283309, ISSN 0006-4971, pages 4532 - 4541, XP055034816 [X] 1-25 * abstract * [Y] 26-35
INTERNATIONAL-SEARCH-REPORT- E. J. CHEADLE ET AL, "Natural Expression of the CD19 Antigen Impacts the Long-Term Engraftment but Not Antitumor Activity of CD19-Specific Engineered T Cells", THE JOURNAL OF IMMUNOLOGY, (20100120), vol. 184, no. 4, doi:10.4049/jimmunol.0901440, ISSN 0022-1767, pages 1885 - 1896, XP055034825 [X] 1-25 * the whole document * [Y] 26-35
OPPOSITION- D39 - Declaration of Christopher Rennie-Smith including CV-
OPPOSITION- D40 - Declaration of Dr Jeffrey C. Pepe, Esq. including Annexes A-C-
OPPOSITION- D41 - Letter to the International Bureau pursuant to Rule 91 PCT-
OPPOSITION- D42 - Declaration of Dr Stanley R. Riddell including CV-
OPPOSITION- D45 - Legal opinion of Derk Visser 14 May 2022-
OPPOSITION- D46 - Hudecek agreement-
OPPOSITION- D47 - Sequence analysis of D29-
OPPOSITION- D48a - Assignments of the priority application US 61/691,117 from Fred Hutchinson Cancer Research Center to Michael Hudecek and Stanley R. Riddell-
OPPOSITION- D48b - Assignments of the priority application US 61/691,117 from Seattle Children’s Hospital to Michael Jensen-
OPPOSITION- D49.1-28 Armitage Exhibit 1-28-
OPPOSITION- D50.1-34 Stoll Exhibit 1-34-
OPPOSITION- D50 - Stoll Declaration-
OPPOSITION- D56 - Decision by the Board of Appeal T2360-19 - 3.3.08-
OPPOSITION- D57 - Ramsey decalaration and exhibits-
OPPOSITION- D6 - Assignments of Michael Hudecek dated August 03, 2013, of Michael Jensen dated August 09, 2013 and of Stanley R. Riddell dated July 29, 2013-
OPPOSITION- D7 - Expert declaration of Hon. Randall R. Rader (July 30, 2021), the former Chief Judge on the United States Court of Appeals for the Federal Circuit, accompanied by-
OPPOSITION- Jiri Novotny, Jürgen Bajorath , "Computational Biochemistry of Antibodies and T-Cell Receptors", Antigen binding molecules: antibodies and t-cell receptors, Academic Press, (19960101), pages 222 - 225, ISBN 0-12-034249-9, XP055920396-
OPPOSITION- Ortolani Claudio, "CD19 Antigen", Ortolani Claudio, Claudio Ortolani, Flow Cytometry of Hematological Malignancies, Wiley, (20110715), pages 48 - 50, doi:10.1002/9781444398069.ch1, ISBN 978-1-4443-9806-9, XP093240024
OPPOSITION- Kevin J. Curran, Hollie Curran, Renier Pegram, Brentjens, "Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions", The Journal of Gene Medicine, John Wiley & Sons, Inc, US, US , (20120627), vol. 14, no. 6, doi:10.1002/jgm.2604, ISSN 1099-498X, pages 405 - 415, XP055081970
OPPOSITION- Hudecek Michael, Maria-Teresa Lupostanghellini, Jiahui Yang, Paula Kosasih, Paulina Paszkiewicz, Jeannette Bet, David G Maloney, Michael C. Jensen, Christoph Rader, Stanley R. Riddell, "5.53 The Anti-Tumor Reactivity of ROR1-CAR Modified T Cells Depends on the Targeted Epitope, CAR-Affinity and Design of the CAR Extracellular Domain", Clinical Lymphoma Myeloma and Leukemia, Elsevier, NL, NL , (20111001), vol. 11, no. S2, doi:10.1016/j.clml.2011.09.207, ISSN 2152-2650, pages S280 - S281, XP093240035
OPPOSITION- Cameron J Turtle; Stanley R Riddell;, "Genetically retargeting CD8lymphocyte subsets for cancer immunotherapy", Current Opinion in Immunology, ELSEVIER, OXFORD., GB, GB , vol. 23, no. 2, doi:10.1016/j.coi.2010.12.012, ISSN 0952-7915, pages 299 - 305, XP028160383
OPPOSITION- Cameron J Turtle, Hudecek Michael, Jensen Michael C, Riddell Stanley R, "Engineered T cells for anti-cancer therapy", Current Opinion in Immunology, ELSEVIER, OXFORD., GB, GB , (20121001), vol. 24, no. 5, doi:10.1016/j.coi.2012.06.004, ISSN 0952-7915, pages 633 - 639, XP055272888
OPPOSITION- Strohl, W.R., "Optimization of Fc-mediated effector functions of monoclonal antibodies", Current Opinion in Biotechnology, LONDON, GB, GB , (20091201), vol. 20, no. 6, doi:10.1016/j.copbio.2009.10.011, ISSN 0958-1669, pages 685 - 691, XP026778879
OPPOSITION- NICHOLSON I C ET AL, "Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma.", Molecular Immunology, PERGAMON, GB, GB , (19971101), vol. 34, no. 16-17, doi:10.1016/S0161-5890(97)00144-2, ISSN 0161-5890, pages 1157 - 1165, XP002220979
OPPOSITION- Klesmith Justin R., Wu Lan, Lobb Roy R., Rennert Paul D., Hackel Benjamin J., "Fine Epitope Mapping of the CD19 Extracellular Domain Promotes Design", Biochemistry, American Chemical Society, (20191203), vol. 58, no. 48, doi:10.1021/acs.biochem.9b00808, ISSN 0006-2960, pages 4869 - 4881, XP055920399
OPPOSITION- Hombach A; Hombach A A; Abken H, "Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended initiation of an innate immune response", Gene Therapy, Nature Publishing Group, London, GB, GB , (20100617), vol. 17, no. 10, doi:10.1038/gt.2010.91, ISSN 0969-7128, pages 1206 - 1213, XP037770859
OPPOSITION- Zola H; MacArdle P J; Bradford T; Weedon H; Yasui H; Kurosawa Y, "Preparation and characterization of a chimeric CD19 monoclonal antibody", IMMUNOLOGY AND CELL BIOLOGY, CARLTON, AU, AU , (19911201), vol. 69, no. 6, doi:10.1038/icb.1991.58, ISSN 0818-9641, pages 411 - 422, XP008115309
OPPOSITION- Marie Bleakley, Stanley R Riddell, "Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia", IMMUNOLOGY AND CELL BIOLOGY, CARLTON, AU, AU , (20110301), vol. 89, no. 3, doi:10.1038/icb.2010.124, ISSN 0818-9641, pages 396 - 407, XP055663061
OPPOSITION- Michael C. Milone, Jonathan D. Fish, Carmine Carpenito, Richard G. Carroll, Gwendolyn K. Binder, David Teachey, Minu Samanta, Mehdi Lakhal, Brian Gloss, Gwenn Danet-Desnoyers, Dario Campana, James L. Riley, Stephan A. Grupp, Carl H. June, "Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.", Molecular Therapy, (20090801), vol. 17, no. 8, doi:10.1038/MT.2009.83, ISSN 1525-0016, pages 1453 - 1464, XP002732433
OPPOSITION- Donald B Kohn, Gianpietro Dotti, Renier Brentjens, Barbara Savoldo, Michael Jensen, Laurence Jn Cooper, Carl H June, Steven Rosenberg, Michel Sadelain, Helen E Heslop, "CARs on Track in the Clinic", Molecular Therapy, Elsevier, (20110301), vol. 19, no. 3, doi:10.1038/mt.2011.1, ISSN 1525-0016, pages 432 - 438, XP055122212
OPPOSITION- SADELAIN M, RIVIERE I, BRENTJENS R, "TARGETING TUMOURS WITH GENETICALLY ENHANCED T LYMPHOCYTES", Nature Reviews Cancer, Nature Pub. Group, London, London , (20030101), vol. 03, no. 01, doi:10.1038/nrc971, ISSN 1474-175X, pages 35 - 45, XP009026020
OPPOSITION- Kochenderfer J N; Rosenberg S A, "Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors", NATURE REVIEWS CLINICAL ONCOLOGY, Nature, NY, US, NY, US , (20130501), vol. 10, no. 5, doi:10.1038/nrclinonc.2013.46, ISSN 1759-4774, pages 267 - 276, XP009170183
OPPOSITION- Carl H. June, Bruce R. Blazar, James L. Riley, "Engineering lymphocyte subsets: tools, trials and tribulations", Nature Reviews Immunology, Nature Publishing Group UK, London, London, (20091001), vol. 9, no. 10, doi:10.1038/nri2635, ISSN 1474-1733, pages 704 - 716, XP055145648
OPPOSITION- Imai C; Mihara K; Andreansky M; Nicholson I C; Pui C-H; Geiger T L; Campana D, "Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.", Blood Cancer Journal, Nature Publishing Group UK, London, London, (20040401), vol. 18, no. 4, doi:10.1038/sj.leu.2403302, ISSN 0887-6924, pages 676 - 684, XP002579934
OPPOSITION- Rob C. Aalberse, Janine Schuurman, "IgG4 breaking the rules", Cancer research, Wiley-Blackwell Publishing Ltd., GB, GB , (20020101), vol. 105, no. 1, doi:10.1046/j.0019-2805.2001.01341.x, ISSN 0019-2805, pages 9 - 19, XP055115132
OPPOSITION- David L. Porter, Bruce L. Levine, Michael Kalos, Adam Bagg, Carl H. June, "Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia", The New England journal of medicine, Massachusetts Medical Society, US, US , (20110825), vol. 365, no. 8, doi:10.1056/NEJMoa1103849, ISSN 0028-4793, pages 725 - 733, XP055579937
OPPOSITION- Gianpietro Dotti, Savoldo Barbara, Brenner Malcolm, "Review Fifteen Years of Gene Therapy Based on Chimeric Antigen Receptors: ''Are We Nearly There Yet?''", HUMAN GENE THERAPY, Mary Ann Liebert, Inc. Publishers, GB, GB , (20091101), vol. 20, no. 11, doi:10.1089/hum.2009.142, ISSN 1043-0342, pages 1229 - 1239, XP055122213
OPPOSITION- Mare Whitlow, Brian A. Bell, Sheau-Line Feng, David Filpula, Karl D. Hardman, Steven L. Hubert, Michele L. Rollence, James F. Wood, Margaret E. Schott, Diane E. Milenic, Takashi Yokota, Jeffrey Schlom, "An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability", Protein Engineering, Design and Selection, Oxford University Press, (19930101), vol. 6, no. 8, doi:10.1093/protein/6.8.989, ISSN 1741-0126, pages 989 - 995, XP055671247
OPPOSITION- Kalos M; Levine B L; Porter D L; Katz S; Grupp S A; Bagg A; June C H, "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia", SCIENCE TRANSLATIONAL MEDICINE, American Association for the Advancement of Science, (20110810), vol. 3, no. 95, doi:10.1126/scitranslmed.3002842, ISSN 1946-6234, pages 95ra73.1 - 95ra73.11, XP002667262
OPPOSITION- Marc Cartellieri, Michael Bachmann, Anja Feldmann, Claudia Bippes, Slava Stamova, Rebekka Wehner, Achim Temme, Marc Schmitz, "Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.", Journal of Biomedicine and Biotechnology, Hindawi Pub. Corp., (20100101), vol. 2010, no. 956304, doi:10.1155/2010/956304, ISSN 1110-7243, pages 1 - 13, XP002673541
OPPOSITION- C. M. Kowolik, M. S. Topp, S. Gonzalez, T. Pfeiffer, S. Olivares, N. Gonzalez, D. D. Smith, S. J. Forman, M. C. Jensen, L. J.N. Cooper, "CD28 Costimulation Provided through a CD19-Specific Chimeric Antigen Receptor Enhances In vivo Persistence and Antitumor Efficacy of Adoptively Transferred T Cells", Cancer research, University of Chicago Press, (20061115), vol. 66, no. 22, doi:10.1158/0008-5472.CAN-06-0160, ISSN 0008-5472, pages 10995 - 11004, XP055044266
OPPOSITION- HUDECEK et al., "Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells", Clinical Cancer Research, (20130000), vol. 19, no. 12, doi:10.1158/1078-0432.CCR-13-0330, pages 3153 - 3164, XP055177780
OPPOSITION- Hudecek M, M-T Lupo-Stanghellini; Kosasih P L; Sommermeyer D; Jensen M C; Rader C; Riddell S R, "Supplementary data: Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells", Clinical Cancer Research, Association for Cancer Research, US, US, (20130615), vol. 19, no. 12, doi:10.1158/1078-0432.CCR-13-0330, ISSN 1078-0432, pages 1 - 8, XP093239914
OPPOSITION- M. Hudecek, D. Sommermeyer, P. L. Kosasih, A. Silva-Benedict, L. Liu, C. Rader, M. C. Jensen, S. R. Riddell, "The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity", Cancer Immunology Research, American Association for Cancer Research, US, US , (20150201), vol. 3, no. 2, doi:10.1158/2326-6066.CIR-14-0127, ISSN 2326-6066, pages 125 - 135, XP055177300
OPPOSITION- L. J. N. Cooper, "T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect", Blood, American Society of Hematology, US, US , (20030215), vol. 101, no. 4, doi:10.1182/blood-2002-07-1989, ISSN 0006-4971, pages 1637 - 1644, XP055204920
OPPOSITION- Hudecek Michael; Silva Anne; Kosasih Paula L.; Chen Yvonne Y.; Turtle Cameron J.; Jensen Michael C.; Riddell Stanley R., "The Non-Signaling Extracellular Spacer Domain of CD19-Specific Chimeric Antigen Receptors Is Decisive for in Vivo Anti-Tumor Activity", Blood, American Society of Hematology, US, US , (20121116), vol. 120, no. 21, doi:10.1182/blood.V120.21.951.951, ISSN 0006-4971, page 951, XP086660651
OPPOSITION- Roberts M R; Qin L; Zhang D; Smith D H; Tran A C; Dull T J; Groopman J E; Capon D J; Byrn R A; Finer M H, "TARGETING OF HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CELLS BY CD8+T LYMPHOCYTES ARMED WITH UNIVERSAL T-CELL RECEPTORS.", Blood, American Society of Hematology, US, US , (19941101), vol. 84, no. 9, doi:10.1182/blood.v84.9.2878.2878, ISSN 0006-4971, pages 2878 - 2889, XP000601097
OPPOSITION- Mitsuyasu R T; Anton P A; Deeks S G; Scadden D T; Connick E; Downs M T; Bakker A; Roberts M R; June C H; Jalali S; Lin A A; Pennathur-Das R; Hege K M, "Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus-infected subjects", Blood, American Society of Hematology, US, US , (20000801), vol. 96, no. 3, doi:10.1182/blood.V96.3.785, ISSN 0006-4971, pages 785 - 793, XP002953226
OPPOSITION- Gu Runxia, Liu Fang, Zou Dehui, Xu Yingxi, Lu Yang, Liu Bingcheng, Liu Wei, Chen Xiaojuan, Liu Kaiqi, Guo Ye, Gong Xiaoyuan, Lv Rui, Chen Xia, Zhou Chunlin, Zhong Mengjun, Wang Huijun, Wei Hui, Mi Yingchang, Qiu Lugui, Lv Lulu, Wang Min, Wang Ying, Zhu Xiaofan, Wang Jianxiang, "Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia", Journal of Hematology & Oncology, BioMed Central Ltd, London UK, London UK , (20201201), vol. 13, no. 1, doi:10.1186/s13045-020-00953-8, ISSN 1756-8722, pages 122 - 13, XP055920402
OPPOSITION- Reineke Ulrich, Mike Schutkowski, "Front Matter: Epitope mapping protocols", Epitope Mapping Protocols : Second Edition, Humana Press, (20090520), vol. 1, pages i - xiii, doi:10.1385/0896033759, ISSN 1064-3745, ISBN 978-1-934115-17-6, XP093239938
OPPOSITION- Carlos A Ramos, Gianpietro Dotti, "Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy", Expert Opinion on Biological Therapy, (20110701), vol. 11, no. 7, doi:10.1517/14712598.2011.573476, ISSN 14712598, pages 855 - 873, XP055122639
OPPOSITION- Michael Hudecek, Anderson Jr Larry D, Nishida Tetsuya, Riddell Stanley R, "Adoptive T-cell therapy for B-cell malignancies", Expert review of hematology, Expert Reviews Ltd, UK, UK , (20091001), vol. 2, no. 5, doi:10.1586/ehm.09.47, ISSN 1747-4086, pages 517 - 532, XP055034818
OPPOSITION- Bridgeman John S; Hawkins Robert E; Hombach Andreas A; Abken Hinrich; Gilham David E, "Building Better Chimeric Antigen Receptors for Adoptive T Cell Therapy", Current Gene Therapy, Bentham Science Publishers Ltd., NL, NL , (20100401), vol. 10, no. 2, doi:10.2174/156652310791111001, ISSN 1566-5232, pages 77 - 90, XP009187229
OPPOSITION- Marco L. Davila, Renier Brentjens, Xiuyan Wang, Isabelle Rivière, Michel Sadelain, "How do CARs work? : Early insights from recent clinical studies targeting CD19", Oncoimmunolgy, Landes Bioscience, US, US , (20121201), vol. 1, no. 9, doi:10.4161/onci.22524, ISSN 2162-4011, pages 1577 - 1583, XP055445746

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents